The technologies being developed by AbGenics are directed towards a new generation of antibiotics and diagnostics, using recombinant antibodies of Camelid, mouse and human formats. Chemi-resistive biosensors for detection of trace amounts of biomarkers and pathogens in the blood of patients are being developed.  Antibody libraries directed against specific pathogens were made, hits isolated and were fused with potent antimicrobials to increase their efficacy creating a new class of antimicrobials called (Abtid®). Vectors for probiotic Lactobacillus mediated delivery of these molecules to the site of action have also been developed. These Lactobacilli are also used to deliver RNAi molecules to the gut to control geohelminth parasite infections.